<DOC>
	<DOCNO>NCT02754960</DOCNO>
	<brief_summary>Background : Repeated bleed gastrointestinal vascular malformation remain major therapeutic challenge . Methods : The investigator perform randomised , double-blind , placebo-controlled , single centre study ass long-term efficacy safety thalidomide 100mg qn p.o . placebo 100 mg qn p.o . administration 4 month subject recurrent gastrointestinal bleeding due vascular malformation . Patients least six episode bleed prior year due vascular malformation randomly group , prescribe four-month regimen either 100mg thalidomide 100 mg placebo orally one time daily , monitor least one year . The primary end point define patient whose rebleeds decrease baseline ≥ 50 % 12 month . Rebleeding define base positive fecal occult blood test ( FOBT ) ( monoclonal colloidal gold color technology ) visit treatment . Secondary outcome include change baseline participant dependent blood transfusion transfuse packed red cell unit , bleed episode , bleed duration , hemoglobin level 12 month . Statistical significance define P &lt; 0.05 .</brief_summary>
	<brief_title>Efficacy Study Thalidomide Gastrointestinal Vascular Malformation Related Bleeding</brief_title>
	<detailed_description>Study design : The study carry single-centre , randomize , double-blind , parallel-group , placebo-controlled phase II study subject recurrent gastrointestinal bleeding due vascular malformation . Subjects Enrollment Assignment : Approximately 100 patient age 40-85 year recurrent gastrointestinal bleeding ( melena and/or fresh hematemesis positive FOBT ) least 6 time within one year , verify vascular malformation capsule endoscopy enteroscopies baseline . Randomization perform proc plan procedure SAS , use method randomly permute block 4 . Within block , number patient allocate two treatment equal . Subjects eligible randomisation give subject number consecutive order within block , investigational product pack corresponding number . The subject allocate one two treatment group , i.e . Thalidomide placebo , accord computer generate list provide Pharmaceutical Co. , Ltd. Chang Zhou , China . If subject discontinues study , subject number reuse , subject allow re-enter study . Intervention : The included patient prospectively randomize two group : thalidomide group placebo group ( Thalidomide group : Thalidomide p.o . 100 mg 4 month , qn ; Placebo group : Placebo thalidomide p.o . 100 mg 4 month , qn ) . The following concomitant medication allow study interfere disease study : Anti-angiogenic agent putative immunomodulators , Anti-platelet drug , anticoagulant , Chinese medication ( salicylate ) , gingko , Echinacea , Somatostatin Heparin , Warfarin ( include Vit K antagonist ) , NSAIDs ( include low dose ) ; potential risk drug-drug interaction : Paxil ( paroxetine ) , Mysoline ( primidone ) , Keppra ( levetiracetam ) , Plaquenil ( hydroxychloroquine ) , St John 's Wort ( st. john 's wort ) , Tegretol ( carbamazepine ) , Zometa ( zoledronic acid ) . Assessment response adverse event : The primary end point define patient whose rebleeds decrease baseline ≥ 50 % 12 month . Rebleeding define base positive fecal occult blood test ( FOBT ) ( monoclonal colloidal gold color technology ) visit treatment . The secondary outcome include change baseline participant dependent blood transfusion transfuse packed red cell unit , bleed episode , bleed duration , hemoglobin level 12 month . An adverse event ( AE ) development undesirable medical condition deterioration pre-existing medical condition follow exposure pharmaceutical product , whether consider causally related product . A serious adverse event AE occur study phase ( ie , run-in , treatment , follow-up ) , dose investigational product , comparator placebo , fulfil one follow criterion : Results death ; Deep vein thrombosis ( DVT ) ; Is immediately life-threatening ; Requires prolongation exist hospitalisation ; Results persistent significant disability incapacity ; Is congenital abnormality birth defect ; Is important medical event may jeopardise subject may require medical intervention prevent one outcomes list . Evaluation Patients Follow-up : - Certified research nurse collect information demographic medical social history patient enrol study . - After screen baseline evaluation , patient closely monitored hospital least one week . They follow twice monthly four-mouth course treatment month thereafter . - Clinical follow-up perform qualified doctor . At visit , bleeding-related parameter ( number duration ) , physical examination perform laboratory value obtain FOBT , complete blood count , serum chemistry , hepatic renal function . Neuropathy adverse event also assess . - Patients advise refrain non-prescribed medicine , especially rebleeding-related medication aspirin , NSAIDs , anti-platelet drug , anticoagulant , Chinese medication ( salicylate ) , gingko , Echinacea .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age 4085 year ; woman postmenopausal , posttubal ligation , form birth control like longterm lay contraceptive ring use condom ; History least six documented gastrointestinal bleeding episode year prior randomization , refractory inaccessible endoscopic therapy surgical ectomy ; Confirmed diagnosis vascular malformation esophagogastroduodenoscopy ( EGD ) , capsule endoscope ( CE ) , doubleballoon endoscope ( DBE ) , colonoscopy , obvious infectious , neoplastic , specific diagnosis ; Angiodysplasia endoscopy characterize focal diffuse venous/capillary lesion present bright red ectatic vessel pulsatile red protrusion , surround venous dilatation patchy erythema without ooze ; Less 1 year bleed history ; GI bleeding cause Esophageal varix , Mallory Weiss syndrome , ZollingerEllison syndrome , Suspicion gastric malignancy baseline endoscopy , PostBillrothresection , Biliary disorder , Gastrointestinal tumor , Crohn 's disease Ulcerative colitis , Hemangioma unknown source GI bleeding ; Bleeding need emergent endoscopic treatment surgery ; Any significant `` alarm symptom '' within past 6 month , , unintentional weight loss , sign gastrointestinal bleed 2 week prior enrolment , jaundice , sign indicate serious malignant disease ; Malignancy clinically significant cardiovascular , pulmonary , renal , pancreatic , hepatic disease , cirrhotic portal hypertension gastropathy , rheumatologic disorder , uncontrollable diabetes mellitus hypertension judge investigator ; A history severe bilateral peripheral neuropathy seizure activity , thromboembolic disease ; A history treatment dose systemic oral topical corticosteroid aspirin , NSAIDs , antiplatelet drug , anticoagulant , Chinese medication ( salicylate ) , gingko , Echinacea , putative immunomodulators antiangiogenic agent ; Haemorrhagic disorder , platelet &lt; 100 x 109/ L , APTT &gt; 1.5x upper limit normal ( ULN ) , treatment lowmolecular weight heparin ; Need continuous concurrent therapy study period NSAIDs , ASA ( include low dose ) , Warfarin ( include Vit K antagonist ) , antiplatelet drug , anticoagulant , mephenytoin , atazanavir Chinese medication ( salicylate ) , gingko , Echinacea , putative immunomodulators antiangiogenic agent ; Pregnancy lactation . Woman childbearing potential must either nonpregnant postmenopausal must use reliable form contraception study period , judged investigator ; Allergy study medication ; Currently undergo systemic cancer chemotherapy receive radiation underwent systemic cancer chemotherapy receive radiation treatment . Use investigational compound participation another clinical trial within 30 day prior start study medication ; Alcohol and/or drug abuse ( addiction drug dependence ) condition associate poor compliance , include expect noncooperation , judge investigator ; Previous participation study ; Involvement plan conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Gastrointestinal bleeding</keyword>
	<keyword>Vascular malformation</keyword>
	<keyword>Angiodysplasia</keyword>
	<keyword>Thalidomide</keyword>
</DOC>